OCEAN BIOMEDICAL

Ocean Biomedical is a biopharma startup founded in 2019 with a mission to accelerate the translation of new discoveries into breakthrough medicines. The company collaborates with leading scientists and research institutions to develop a diverse portfolio of pharmaceutical inventions and technologies in the fields of oncology, fibrosis, and the treatment and prevention of severe malaria. Its scientific co-founder, Jack A. Elias, M.D., has made pioneering contributions to the field of chitinase biology, forming the basis of the oncology and fibrosis programs.

In the realm of infectious diseases, the company is focused on combating malaria, with Jonathan Kurtis, M.D., leading the efforts. The company's innovative approach has led to the discovery of two novel malaria antigens, PfSEA-1 and PfGARP, showing promising results in in-vitro and animal model testing. The potential impact of their work is significant, given that malaria claims the lives of 500,000 children and affects 200-300 million people globally each year.

With its last investment of $10.00M from Poseidon Biotech - India in October 4, 2023, Ocean Biomedical demonstrates its appeal to global investors. This signifies investor confidence in the company's innovative approach and potential for developing groundbreaking medical solutions, reflecting a promising trajectory for the company.

Ocean Biomedical's commitment to empowering great medical science, combined with its strategic partnerships, positions it as a formidable player in the biotechnology and health care industries.